Patent · US Active

Combination drugs of hypoxanthine and human immunoglobulin

US12186323B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignees

Institute of Blood Transfusion, Chinese Academy of Medical Sciences · CN
INSTITUTE OF RADIATION MEDICINE CHINESE ACADEMY OF MEDICAL SCIENCES · CN
Shanghai RAAS Blood Products Co., Ltd. · CN

Inventors

Zongkui Wang · Sichuan, CN
Ming Cui · Shandong, CN
Changqing Li · Bloomington, US
Jun Xu · Mason, US
Lu Cheng · Taipei, TW

Key dates

Filing date	Jul 11, 2022
Grant date	Jan 7, 2025
Priority date	—
Expiry date	Sep 16, 2042

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A combination drug contains hypoxanthine and human immunoglobulin (HIg). HIg has a therapeutic effect on radiation injuries, and the combination of hypoxanthine and HIg can further enhance this therapeutic effect. The combination drug can be administered to patients undergoing radiotherapy and to those who accidentally have excessive irradiation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.